Uterine transverse diameter and risk of LNG-IUS malposition in adenomyosis patients: a threshold effect analysis from a retrospective cohort study

子宫横径与子宫腺肌症患者左炔诺孕酮宫内节育系统(LNG-IUS)位置异常风险:一项回顾性队列研究的阈值效应分析

阅读:1

Abstract

OBJECTIVE: The malposition of the levonorgestrel-releasing intrauterine system (LNG-IUS) can have a considerable impact on the treatment outcomes for patients with adenomyosis. This study was designed to explore the relationship between the transverse diameter of the uterus and the occurrence of LNG-IUS malposition. METHODS: This retrospective cohort study enrolled 99 adenomyosis patients treated at Fujian Maternity and Child Health Hospital between May 2021 and May 2023. Preoperative uterine transverse diameter was measured using transvaginal ultrasound examinations. We defined LNG-IUS malposition as either downward displacement or expulsion of the device. Data analysis employed Cox regression models with adjustments for relevant demographic, clinical, and laboratory variables. RESULTS: Our analysis revealed a notable non-linear relationship between the transverse diameter of the uterus and subsequent risk of LNG-IUS malposition. We identified 5.4 cm as a significant clinical threshold; beyond this measurement, the risk increased substantially, with malposition hazard rising by 112% per additional centimeter (HR 2.12; 95% CI, 1.28-3.49; p = 0.003). Among the subgroup of patients suffering from severe dysmenorrhea (VAS ≥ 7), this association was considerably stronger, yielding a hazard ratio of 3.43 (95% CI, 1.32-8.89; p = 0.011). CONCLUSION: Patients with adenomyosis whose uterine transverse diameter exceeds 5.4 cm face a higher risk of LNG-IUS malposition. This measurement threshold provides clinicians a practical tool for assessing suitable candidates for LNG-IUS placement, which may lead to better outcomes in this patient group.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。